Novavax Hits Profit in Q4 2025 & Raises 2026 Revenue Forecast
Novavax reports strong 2025 results, first Q4 profit in years, and boosts 2026 outlook thanks to Pfizer & Sanofi deals.
/ 45 items
#PFE↓
Pfizer’s Chantix Move Seen as Positive Signal for Achieve Life Sciences
Analysts say Pfizer listing Chantix on TrumpRx may support Achieve Life Sciences and boost confidence in cytisinicline’s approval prospects.
Pfizer Q4 2025: Strong Performance Despite COVID Decline
Pfizer beats Q4 estimates with $17.6B revenue as legacy drugs offset COVID sales drop. Obesity drug shows 12.3% weight loss. 2026 guidance reaffirmed.
Novavax Partners with Pfizer: $30M Deal for Vaccine Technology
Novavax secures $30M upfront payment from Pfizer in licensing deal for Matrix-M adjuvant technology, with potential for $500M more in milestone payments.
Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.
Moderna Rises as CEO Eyes European Market and Flu-Covid Vaccine
Moderna stock jumps 14%, driven by European expansion plans and a new flu-Covid combo vaccine aiming for 2026 approval.